NightFood Holdings, Inc. 8-K

What Happened

• NightFood Holdings, Inc. (through its wholly owned subsidiary TechForce Robotics, Inc.) announced on March 31, 2026 that it entered a Joint Development, Manufacturing and Licensing Agreement with Oncotelic Therapeutics, Inc. to jointly develop, manufacture and commercialize AI‑enabled, GMP‑compliant robotic systems for pharmaceutical and related manufacturing environments.
• The agreement covers the full product lifecycle from design and development through manufacturing readiness and commercial deployment. Funding, resources, and milestone payments will follow written statements of work; milestone payments are due within 30 days after both parties confirm achievement.

Key Details

• Agreement date: March 31, 2026; initial term: 1 year with automatic renewals for successive five‑year terms unless terminated.
• IP allocation: Oncotelic owns AI‑related foreground IP (including improvements to its PDAOAI platform); TechForce owns solely developed robotic hardware; jointly developed IP will be jointly owned. All data generated by Product operation/testing is owned exclusively by NightFood (the Company).
• Exclusivity restriction: During the term and for 12 months after termination, TechForce may not license, transfer or otherwise provide third‑party access to the Joint IP for use in pharmaceutical/biopharmaceutical manufacturing.
• Commercial terms (revenue sharing, royalties, profit splits) will be negotiated and documented in a separate Commercialization and Licensing Agreement to be executed before the first commercial sale.

Why It Matters

• This is a material commercial and technology collaboration that expands NightFood’s TechForce unit into AI‑enabled, GMP robotic systems for pharma manufacturing—a new product area that could create future licensing, RaaS (robotics‑as‑a‑service) or product revenue streams if commercialized.
• Key business levers (commercial financial terms, revenue shares and licensing fees) are not yet set and will be defined in a later agreement, so investors should view this as an early‑stage commercial partnership rather than immediate revenue recognition.
• The IP and data ownership provisions, plus the 12‑month restriction on TechForce licensing joint IP to third parties in pharma manufacturing, shape how NightFood can monetize the technology and partner with others going forward.

Note: NightFood furnished (but did not file) a press release on April 6, 2026 under Regulation FD; the full agreement and press release are included as exhibits to the 8‑K.